New agents for the treatment of Hepatitis C

被引：5

作者：

Buti, Maria ^{[1
]}

Horns, Maria ^{[2
]}

机构：

[1] Hosp Univ Vall dHebron, Serv Med Interna Hepatol, Vall Dhebron, Spain

[2] Hosp Univ Vall dHebron, Serv Bioquim, Vall Dhebron, Spain

来源：

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2012年 / 30卷 / 03期

关键词：

Chronic Hepatitis C; Protease inhibitors; Sustained virological response; Antiviral resistances; VIRUS EPIDEMIOLOGY; TELAPREVIR; REPLICATION; BOCEPREVIR; RIBAVIRIN; PROTEASE;

D O I：

10.1016/j.eimc.2011.09.012

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The current treatment of Chronic Hepatitis C (CHC) is based on the combination of peginterferon alpha 2a or 2b and ribavirin. This treatment achieves Sustained Virological Response (SVR) rates in more than 50% of the patients. The SVR rates are higher in genotype 2 and 3 patients than in genotype 1, which account for more than 50%. For this reason, the development of new drugs is needed. The knowledge of Hepatitis C Virus (HCV) replication cycle and the characterisation of the viral enzymes allow targets to be defined with the ability to inhibit HCV enzymes. The present overview analyses the first two NS3/NS4 protease inhibitors approved for the treatment of CHC, boceprevir and telaprevir. Both increase rates of SVR in naive and in previously treated patients with the advantage that in some cases therapy can be shortened. However, these drugs have new side effects such as a rash and an increase in the rate of anaemia. (C) 2011 Elsevier Espana, S.L. All rights reserved.

引用

页码：147 / 150

页数：4

共 21 条

[1] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[2] KINETIC AND STRUCTURAL-ANALYSES OF HEPATITIS-C VIRUS POLYPROTEIN PROCESSING [J].

BARTENSCHLAGER, R ;

AHLBORNLAAKE, L ;

MOUS, J ;

JACOBSEN, H .

JOURNAL OF VIROLOGY, 1994, 68 (08) :5045-5055

[3] Replication of the hepatitis C virus [J].

Bartenschlager, R ;

Lohmann, V .

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2000, 14 (02) :241-254

[4] A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel [J].

Cornberg, Markus ;

Razavi, Homie A. ;

Alberti, Alfredo ;

Bernasconi, Enos ;

Buti, Maria ;

Cooper, Curtis ;

Dalgard, Olav ;

Dillion, John F. ;

Flisiak, Robert ;

Forns, Xavier ;

Frankova, Sona ;

Goldis, Adrian ;

Goulis, Ioannis ;

Halota, Waldemar ;

Hunyady, Bela ;

Lagging, Martin ;

Largen, Angela ;

Makara, Michael ;

Manolakopoulos, Spilios ;

Marcellin, Patrick ;

Marinho, Rui T. ;

Pol, Stanislas ;

Poynard, Thierry ;

Puoti, Massimo ;

Sagalova, Olga ;

Sibbel, Scott ;

Simon, Krzysztof ;

Wallace, Carolyn ;

Young, Kendra ;

Yurdaydin, Cihan ;

Zuckerman, Eli ;

Negro, Francesco ;

Zeuzem, Stefan .

LIVER INTERNATIONAL, 2011, 31 :30-60

[5] AN AMINO-TERMINAL DOMAIN OF THE HEPATITIS-C VIRUS NS3 PROTEASE IS ESSENTIAL FOR INTERACTION WITH NS4A [J].

FAILLA, C ;

TOMEI, L ;

DEFRANCESCO, R .

JOURNAL OF VIROLOGY, 1995, 69 (03) :1769-1777

[6] Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus [J].

Garg, Varun ;

van Heeswijk, Rolf ;

Lee, Jee Eun ;

Alves, Katia ;

Nadkarni, Priya ;

Luo, Xia .

HEPATOLOGY, 2011, 54 (01) :20-27

[7] The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus [J].

Gentile, Ivan ;

Carleo, Maria Aurora ;

Borgia, Federico ;

Castaldo, Giuseppe ;

Borgia, Guglielmo .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (01) :151-159

[8] Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor [J].

Ghosal, Anima ;

Yuan, Yuan ;

Tong, Wei ;

Su, Ai-Duen ;

Gu, Chunyan ;

Chowdhury, Swapan K. ;

Kishnani, Narendra S. ;

Alton, Kevin B. .

DRUG METABOLISM AND DISPOSITION, 2011, 39 (03) :510-521

[9] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

[10] Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo [J].

Kolykhalov, AA ;

Mihalik, K ;

Feinstone, SM ;

Rice, CM .

JOURNAL OF VIROLOGY, 2000, 74 (04) :2046-2051

← 1 2 3 →